PE-22-28
CognitiveTREK-1 research peptideExperimental
Heptapeptide analog of spadin that blocks TREK-1 potassium channels in antidepressant-model research. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 1801959-12-5
- Molecular Weight (MW)
- 773.9 g/mol
- Half-life
- —
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Research-dependent
- Last updated
- 8/23/2026
- Targets
- TREK-1 (KCNK2)
Overview
Heptapeptide analog of spadin that blocks TREK-1 potassium channels in antidepressant-model research. Not FDA-approved.
Protocol
- Dosage Range
- Per published research protocol — not a clinical label
- Frequency
- Research-dependent
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Short peptide derived from sortilin/spadin biology that inhibits the TREK-1 (KCNK2) channel, producing rapid antidepressant-like effects in rodents.
Targets
TREK-1 (KCNK2)
Studies
- Spadin / TREK-1 antidepressant peptide— Journal/year not available
Benefits
Depression-model research tool
Potential Side Effects
- No established human AE profile
References
- PMID 20439730External link · Year —